AbbVie Inc. cash flow to debt ratio of 27.55% indicates that the company generates enough cash to cover its debts. This level indicates strong financial health.

AbbVie Inc.'s free cash flow has decreased 0.09% from $17.83B last year to $17.82B, signaling decreasing performance

AbbVie Inc.'s debt to equity ratio is -11.93, signaling that the company spent its equity and risk bankruptcy.

AbbVie Inc.'s debt to equity ratio is -11.93, signaling that the company spent its equity and risk bankruptcy.

AbbVie Inc. has a net debt to EBITDA ratio of 3.62x, which exceeds the 3.00x threshold, indicating high leverage and potential financial risk

AbbVie Inc.'s interest coverage ratio of 6.73 indicates that earnings with good margin can cover interest payments on company debt

AbbVie Inc.'s profit margin has increased (29.26%) in the last year from 7.59% to 9.82%, signaling increasing performance

AbbVie Inc.'s short-term liabilities of $43.29B exceed its short-term assets of $29.06B, signaling financial risk

AbbVie Inc.'s return on assets of 4.68% is lower than the 5.00% threshold, indicating inefficient asset utilization

AbbVie Inc.'s return on equity of -136.63%, is lower than 15.00%, indicating bad performance

AbbVie Inc.'s operating cash flow exceeds its net income, indicating high-quality earnings backed by actual cash generation

AbbVie Inc. had positive net income in 5 out of 5 years, indicating stable and consistent earnings

AbbVie Inc. has positive free cash flow, indicating the company generates cash after capital expenditures

AbbVie Inc. has a free cash flow yield of 4.07%, which is above the 2.00% threshold, indicating strong cash generation relative to market value

AbbVie Inc.'s yearly earnings has decreased 1.22% since last year from $4.28B to $4.23B, signaling decreasing performance

AbbVie Inc.'s yearly revenue has increased 8.57% since last year from $56.33B to $61.16B, signaling increasing performance

ROIC 13.67% (Source: FMP key-metrics). At or above the 10% threshold. Score: 2 of 2. The company is generating returns above the upper end of the typical US weighted-average cost of capital range under this definition of invested capital.

AbbVie Inc.'s 3-year revenue CAGR of 1.75% is positive, indicating growing revenue over the past 3 years

AbbVie Inc. had revenue growth in 4 out of 5 years, indicating consistent revenue performance

AbbVie Inc. had positive ROE in 4 out of 5 years, indicating consistent and reliable returns on equity

AbbVie Inc. is overvalued relative to its fair value price of 88.01 based on Discounted Cash Flow model

AbbVie Inc. has an earnings yield of 1.44%, which is below the 4.00% threshold, indicating the stock may be expensive relative to its earnings

AbbVie Inc. is overvalued relative to its fair value price of 75.89 based on EBITDA multiple model

AbbVie Inc. has an EV/EBITDA ratio of 28.47x, which exceeds the 20.00x threshold, indicating the stock may be overvalued relative to its operating earnings

AbbVie Inc. is overvalued relative to its fair value price of 199.77 based on Earnings Fair Value model

AbbVie Inc.'s earnings growth over the measurement period is negative; the PEG ratio is not meaningful and the check fails.

AbbVie Inc. has negative shareholder equity; price-to-book is not meaningful and the check fails

AbbVie Inc. has a price-to-sales ratio of 6.82x, which is below the 8.00x threshold, indicating reasonable valuation relative to its revenue